Esmee H Runhart1,2, Mubeen Khan2,3, Stéphanie S Cornelis2,3, Susanne Roosing2,3, Marta Del Pozo-Valero4,5, Tina M Lamey6,7, Petra Liskova8,9, Lisa Roberts10, Heidi Stöhr11, Caroline C W Klaver1,12,13, Carel B Hoyng1,2, Frans P M Cremers2,3, Claire-Marie Dhaenens3,14. 1. Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands. 2. Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands. 3. Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. 4. Department of Genetics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain. 5. Center for Biomedical Network Research on Rare Diseases, Instituto de Salud Carlos III, Madrid, Spain. 6. Centre for Ophthalmology and Visual Science, The University of Western Australia, Nedlands, Western Australia, Australia. 7. Australian Inherited Retinal Disease Registry and DNA Bank, Department of Medical Technology and Physics, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. 8. Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. 9. Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. 10. University of Cape Town/MRC Genomic and Precision Medicine Research Unit, Division of Human Genetics, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. 11. Institute of Human Genetics, University of Regensburg, Regensburg, Germany. 12. Department of Ophthalmology, Erasmus Medical Center, Rotterdam, the Netherlands. 13. Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands. 14. University Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, Lille, France.
Abstract
Importance: The mechanisms behind the phenotypic variability and reduced penetrance in autosomal recessive Stargardt disease (STGD1), often a blinding disease, are poorly understood. Identification of the unknown disease modifiers can improve patient and family counseling and provide valuable information for disease management. Objective: To assess the association of incompletely penetrant ABCA4 alleles with sex in STGD1. Design, Setting, and Participants: Genetic data for this cross-sectional study were obtained from 2 multicenter genetic studies of 1162 patients with clinically suspected STGD1. Unrelated patients with genetically confirmed STGD1 were selected. The data were collected from June 2016 to June 2019, and post hoc analysis was performed between July 2019 and January 2020. Main Outcomes and Measures: Penetrance of reported mild ABCA4 variants was calculated by comparing the allele frequencies in the general population (obtained from the Genome Aggregation Database) with the genotyping data in the patient population (obtained from the ABCA4 Leiden Open Variation Database). The sex ratio among patients with and patients without an ABCA4 allele with incomplete penetrance was assessed. Results: A total of 550 patients were included in the study, among which the mean (SD) age was 45.7 (18.0) years and most patients were women (311 [57%]). Five of the 5 mild ABCA4 alleles, including c.5603A>T and c.5882G>A, were calculated to have incomplete penetrance. The women to men ratio in the subgroup carrying c.5603A>T was 1.7 to 1; the proportion of women in this group was higher compared with the subgroup not carrying a mild allele (difference, 13%; 95% CI, 3%-23%; P = .02). The women to men ratio in the c.5882G>A subgroup was 2.1 to 1, and the women were overrepresented compared with the group carrying no mild allele (difference, 18%; 95% CI, 6%-30%; P = .005). Conclusions and Relevance: This study found an imbalance in observed sex ratio among patients harboring a mild ABCA4 allele, which concerns approximately 25% of all patients with STGD1, suggesting that STGD1 should be considered a polygenic or multifactorial disease rather than a disease caused by ABCA4 gene mutations alone. The findings suggest that sex should be considered as a potential disease-modifying variable in both basic research and clinical trials on STGD1.
Importance: The mechanisms behind the phenotypic variability and reduced penetrance in autosomal recessive Stargardt disease (STGD1), often a blinding disease, are poorly understood. Identification of the unknown disease modifiers can improve patient and family counseling and provide valuable information for disease management. Objective: To assess the association of incompletely penetrant ABCA4 alleles with sex in STGD1. Design, Setting, and Participants: Genetic data for this cross-sectional study were obtained from 2 multicenter genetic studies of 1162 patients with clinically suspected STGD1. Unrelated patients with genetically confirmed STGD1 were selected. The data were collected from June 2016 to June 2019, and post hoc analysis was performed between July 2019 and January 2020. Main Outcomes and Measures: Penetrance of reported mild ABCA4 variants was calculated by comparing the allele frequencies in the general population (obtained from the Genome Aggregation Database) with the genotyping data in the patient population (obtained from the ABCA4 Leiden Open Variation Database). The sex ratio among patients with and patients without an ABCA4 allele with incomplete penetrance was assessed. Results: A total of 550 patients were included in the study, among which the mean (SD) age was 45.7 (18.0) years and most patients were women (311 [57%]). Five of the 5 mild ABCA4 alleles, including c.5603A>T and c.5882G>A, were calculated to have incomplete penetrance. The women to men ratio in the subgroup carrying c.5603A>T was 1.7 to 1; the proportion of women in this group was higher compared with the subgroup not carrying a mild allele (difference, 13%; 95% CI, 3%-23%; P = .02). The women to men ratio in the c.5882G>A subgroup was 2.1 to 1, and the women were overrepresented compared with the group carrying no mild allele (difference, 18%; 95% CI, 6%-30%; P = .005). Conclusions and Relevance: This study found an imbalance in observed sex ratio among patients harboring a mild ABCA4 allele, which concerns approximately 25% of all patients with STGD1, suggesting that STGD1 should be considered a polygenic or multifactorial disease rather than a disease caused by ABCA4 gene mutations alone. The findings suggest that sex should be considered as a potential disease-modifying variable in both basic research and clinical trials on STGD1.
Authors: Frans P M Cremers; Stéphanie S Cornelis; Esmee H Runhart; Galuh D N Astuti Journal: Invest Ophthalmol Vis Sci Date: 2018-11-01 Impact factor: 4.799
Authors: Mubeen Khan; Stéphanie S Cornelis; Muhammad Imran Khan; Duaa Elmelik; Eline Manders; Sem Bakker; Ronny Derks; Kornelia Neveling; Maartje van de Vorst; Christian Gilissen; Isabelle Meunier; Sabine Defoort; Bernard Puech; Aurore Devos; Heidi L Schulz; Heidi Stöhr; Felix Grassmann; Bernhard H F Weber; Claire-Marie Dhaenens; Frans P M Cremers Journal: Hum Mutat Date: 2019-06-18 Impact factor: 4.878
Authors: Nirmal K Sampathkumar; Juan I Bravo; Yilin Chen; Prakroothi S Danthi; Erin K Donahue; Rochelle W Lai; Ryan Lu; Lewis T Randall; Nika Vinson; Bérénice A Benayoun Journal: Hum Genet Date: 2019-11-01 Impact factor: 4.132
Authors: Riccardo Sangermano; Alejandro Garanto; Mubeen Khan; Esmee H Runhart; Miriam Bauwens; Nathalie M Bax; L Ingeborgh van den Born; Muhammad Imran Khan; Stéphanie S Cornelis; Joke B G M Verheij; Jan-Willem R Pott; Alberta A H J Thiadens; Caroline C W Klaver; Bernard Puech; Isabelle Meunier; Sarah Naessens; Gavin Arno; Ana Fakin; Keren J Carss; F Lucy Raymond; Andrew R Webster; Claire-Marie Dhaenens; Heidi Stöhr; Felix Grassmann; Bernhard H F Weber; Carel B Hoyng; Elfride De Baere; Silvia Albert; Rob W J Collin; Frans P M Cremers Journal: Genet Med Date: 2019-01-15 Impact factor: 8.822
Authors: Esmee H Runhart; Patty Dhooge; Magda Meester-Smoor; Jeroen Pas; Jan Willem R Pott; Redmer van Leeuwen; Hester Y Kroes; Arthur A Bergen; Yvonne de Jong-Hesse; Alberta A Thiadens; Mary J van Schooneveld; Maria van Genderen; Camiel Boon; Caroline Klaver; L Ingeborg van den Born; Frans P M Cremers; Carel B Hoyng Journal: Acta Ophthalmol Date: 2021-08-25 Impact factor: 3.988
Authors: Stéphanie S Cornelis; Esmee H Runhart; Miriam Bauwens; Zelia Corradi; Elfride De Baere; Susanne Roosing; Lonneke Haer-Wigman; Claire-Marie Dhaenens; Anneke T Vulto-van Silfhout; Frans P M Cremers Journal: Am J Hum Genet Date: 2022-02-03 Impact factor: 11.043
Authors: Irene Vázquez-Domínguez; Catherina H Z Li; Zeinab Fadaie; Lonneke Haer-Wigman; Frans P M Cremers; Alejandro Garanto; Carel B Hoyng; Susanne Roosing Journal: Invest Ophthalmol Vis Sci Date: 2022-05-02 Impact factor: 4.925
Authors: Nina Kobal; Tjaša Krašovec; Maja Šuštar; Marija Volk; Borut Peterlin; Marko Hawlina; Ana Fakin Journal: Int J Mol Sci Date: 2021-02-21 Impact factor: 5.923
Authors: Maximilian Pfau; Catherine A Cukras; Laryssa A Huryn; Wadih M Zein; Ehsan Ullah; Marisa P Boyle; Amy Turriff; Michelle A Chen; Aarti S Hinduja; Hermann Ea Siebel; Robert B Hufnagel; Brett G Jeffrey; Brian P Brooks Journal: JCI Insight Date: 2022-01-25
Authors: Rachael C Heath Jeffery; Jennifer A Thompson; Johnny Lo; Tina M Lamey; Terri L McLaren; John N De Roach; Dimitar N Azamanov; Ian L McAllister; Ian J Constable; Fred K Chen Journal: Retina Date: 2022-04-24 Impact factor: 3.975
Authors: Anna M Tracewska; Beata Kocyła-Karczmarewicz; Agnieszka Rafalska; Joanna Murawska; Joanna Jakubaszko-Jabłónska; Małgorzata Rydzanicz; Piotr Stawiński; Elżbieta Ciara; Beata S Lipska-Ziętkiewicz; Muhammad Imran Khan; Frans P M Cremers; Rafał Płoski; Krystyna H Chrzanowska Journal: Mol Vis Date: 2021-07-16 Impact factor: 2.367
Authors: Rachael C Heath Jeffery; Syed Aqif Mukhtar; Ian L McAllister; William H Morgan; David A Mackey; Fred K Chen Journal: Ophthalmic Genet Date: 2021-05-03 Impact factor: 1.803